UPDATE 1-GSK hands back failed muscular dystrophy drug to Prosensa
January 13, 2014 at 11:41 AM EST
LONDON, Jan 13 (Reuters) - GlaxoSmithKline has handed back rights to an experimental drug for Duchenne muscular dystrophy to U.S.-listed Dutch biotech firm Prosensa after it failed last year in a critical clinical trial.
